| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 78,360 | 60,228 |
| Depreciation and amortization | 174,345 | 120,272 |
| Unrealized foreign currency gain | 8,606 | 11,813 |
| Amortization of debt issuance costs and discount | 18,716 | 13,686 |
| Reclassification of cash flow hedge | 1,713 | 5,876 |
| Loss on refinancing | -31,365 | - |
| Intangible asset impairment charges | 22,784 | 0 |
| Stock-based compensation | 23,751 | 15,532 |
| Inventory provision | 59,326 | 38,432 |
| Other operating charges and credits, net | -3,575 | -2,254 |
| Trade accounts receivable, net | 110,228 | 32,615 |
| Inventories | 66,846 | 36,039 |
| Prepaid expenses, other current assets and other assets | 20,173 | 10,015 |
| Related party receivables | 830 | 1,108 |
| Accounts payable, accrued expenses and other liabilities | 2,744 | -67,004 |
| Related party payables | 3,107 | 5,293 |
| Net cash provided by operating activities | 209,677 | 91,227 |
| Purchases of property, plant and equipment | 48,290 | 35,992 |
| Acquisition of intangible assets | 12,514 | 5,100 |
| Deposits for future acquisition of property, plant and equipment | 7,384 | 4,632 |
| Proceeds from sale of property, plant and equipment | 1,379 | 1,379 |
| Proceeds from sale of subsidiary | 0 | 0 |
| Net cash used in investing activities | -66,809 | -44,345 |
| Proceeds from issuance of debt | 2,694,750 | - |
| Payments of principal on debt, revolving credit facilities, financing leases and other | 2,805,384 | 251,076 |
| Payments of deferred financing and refinancing costs | 74,973 | 1,745 |
| Borrowings on revolving credit facilities | 218,000 | 218,000 |
| Proceeds from exercise of stock options | 1,407 | 754 |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | 21,957 | 21,828 |
| Tax and other distributions to non-controlling interests | 38,825 | 24,958 |
| Payment of principal on notes payable - related party | 0 | 0 |
| Proceeds from alliance party | 5,572 | - |
| Net cash used in financing activities | -21,410 | -80,853 |
| Effect of foreign exchange rate on cash | -1,471 | -777 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 119,987 | -34,748 |
| Cash and cash equivalents at beginning of period | 118,420 | - |
| Cash and cash equivalents at end of period | 238,407 | - |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)